Skip to main
ACCD
ACCD logo

Accolade (ACCD) Stock Forecast & Price Target

Accolade (ACCD) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 19%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Accolade Inc has demonstrated a commitment to enhancing its technological capabilities, as evidenced by increased cash expenditures on technology and development, which are expected to drive long-term innovation and effectiveness in its healthcare solutions. The company's strategic focus on scalability through a unified platform, coupled with significant advantages from AI integrations and a robust network of condition-specific services, positions Accolade well to improve health outcomes and lower costs for its clients. With projected revenue growth rates of 7.4% for FY25 and 4.5% for FY26, along with positive feedback regarding its new AI-enabled navigation platform, Accolade appears poised to maintain a competitive edge in the evolving healthcare market.

Bears say

Accolade Inc is facing significant headwinds due to anticipated declines in Medicaid enrollment, which are projected to decrease by 8%-10% by year-end, potentially jeopardizing revenue and EBITDA guidance. The company also encounters challenges in customer acquisition, particularly in its online mental health offerings, where high competition has driven costs beyond sustainable levels, affecting unit economics in a high churn market. Additionally, management is navigating inflationary labor costs that are putting pressure on profitability goals while attempting to balance conservative forecasting against reduced employer customer headcounts.

Accolade (ACCD) has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 19% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accolade and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accolade (ACCD) Forecast

Analysts have given Accolade (ACCD) a Buy based on their latest research and market trends.

According to 21 analysts, Accolade (ACCD) has a Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accolade (ACCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.